BioCentury | May 9, 2018
Distillery Therapeutics

Musculoskeletal

...inhibitor Rayzon parecoxib to treat pain. Merck & Co. Inc. markets its COX-2 inhibitor Arcoxia etoricoxib...
BioCentury | Apr 3, 2018
Distillery Therapeutics

Neurology

...cancer and Phase II testing to treat lung cancer. Merck & Co. Inc. markets Arcoxia etoricoxib...
BioCentury | Jan 21, 2013
Clinical News

Arcoxia etoricoxib regulatory update

...The Scottish Medicines Consortium recommended against the use of Merck's Arcoxia etoricoxib on the National Health...
...see BioCentury, June 30, 2008). Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Arcoxia etoricoxib...
BioCentury | Oct 4, 2010
Finance

4Q10 milestones

...1 infection Submit MAA; complete rolling BLA submission YE10 Merck & Co. Inc. (NYSE:MRK) Arcoxia etoricoxib...
BioCentury | Jul 5, 2010
Finance

2H10 milestones

...503034) Chronic HCV genotype 1 infection Submit NDA YE10 Merck & Co. Inc. (NYSE:MRK) Arcoxia etoricoxib...
BioCentury | Dec 22, 2008
Product Development

Taking homework seriously

...FDA's Arthritis Advisory Committee made clear in its review of Merck & Co. Inc. 's Arcoxia...
BioCentury | Jun 30, 2008
Clinical News

Arcoxia etoricoxib regulatory update

...EMEA's CHMP recommended approval of Arcoxia to include treating ankylosing spondylitis, but also recommended that the...
...the safety review after cardiovascular concerns were raised (see BioCentury, Sept. 24, 2007). Merck markets Arcoxia...
...arthritis (RA) and gouty arthritis. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Arcoxia etoricoxib...
BioCentury | Jan 21, 2008
Regulation

Differences of opinion

...NYSE:MRK) 2007: Receives not approvable letter from FDA for Arcoxia to treat osteoarthritis (OA) 2002: Arcoxia...
BioCentury | Jan 21, 2008
Regulation

Political goalposts

...is contingent on demonstration that it meets an unmet medical need; agency states that Arcoxia etoricoxib...
...to marketed NSAIDs and is effective; Merck receives a not approvable letter from FDA for Arcoxia...
BioCentury | Jan 21, 2008
Regulation

System reset in 2008

...safety and/or efficacy. As an example, FDA rejected an application from Merck to market its Arcoxia...
Items per page:
1 - 10 of 74